INTERIM REPORT JANUARY-SEPTEMBER 2012 CHRONTECH PHARMA AB
ET | Source:Fastilium Property Group AB
· Research and development costs amounted to SEK 10.7 (10.5) m
· The loss after tax was SEK -14.9 (-13.9) m
· Earnings per share were SEK -0.08 (-0.14)
· The company had no net sales for the period
· The patient recruitment for the controlled phase II clinical study of
ChronVac-C® in combination with standard-of-care is complete
· The development of ChronTech’s IVIN technology progresses according to plan
For more information, please contact:
Anders Vahlne, CEO and Head of Research, ChronTech Pharma AB
Mobile phone: +46 709 28 05 28,
ChronTech develops the therapeutic DNA vaccines ChronVac-C® and ChronVac-B drugs
against chronic hepatitis C virus and hepatitis B virus infections, i.e. chronic
infections with jaundice causing viruses which can lead to liver cirrhosis and
liver cancer. ChronTech has also developed and further develops a patent pending
new type of injection needle for a more effective uptake of DNA vaccines.
ChronTech also have part ownership in the wound healing therapy ChronSeal®, and
in the new platform technology RAS®. The ChronTech share is admitted to trade on
First North. Remium Nordic AB is Certified Adviser for ChronTech. For more
information, please visit: www.chrontech.se
In the event of any discrepancy between the Swedish and English versions of this
press release, the Swedish version will take precedence.
other press releases byFastilium Property Group AB
GlobeNewswire, a Nasdaq company, is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
2321 Rosecrans Avenue.
El Segundo, CA 90245 Phone: (800) 307-6627 Fax: (800) 307-3567
25 Basinghall Street,
London EC2V 5HA
UK Phone: +1 866-465-8454